Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | CHIEF MEDICAL OFFICER | October 01, 2026 | October 02, 2026 |
| Verve Therapeutics, Inc.VERV · Entity 11259 | 10% owner | June 16, 2021 | June 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,059 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 1,051 · Balance 19,059 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.51 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.51 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Verve Therapeutics, Inc.
Report date June 16, 2021 · Filed June 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 409,626 |
Reported balance
Holding disclosure · report date 2021-06-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 409,626 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 21:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,051 | $26.16 | $27,493.53 |
DisclosureSEC source: 0001780088-26-000023 · form4-10022026_091051.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,059 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.51 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,600 | $31.06 | $49,691.04 |
DisclosureSEC source: 0001780088-26-000021 · form4-09032026_080910.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,110 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.20 per share, inclusive. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,945 | $30.51 | $120,369.84 |
DisclosureSEC source: 0001780088-26-000021 · form4-09032026_080910.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,710 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.94 to $30.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 00:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 242 | $32.47 | $7,857.28 |
DisclosureSEC source: 0001780088-26-000019 · form4-08192026_120845.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,655 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 00:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 4,525 | $32.01 | $144,832.58 |
DisclosureSEC source: 0001780088-26-000019 · form4-08192026_120845.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,897 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| August 14, 2026 Filed Aug 19, 2026 00:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionPerformance Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000019 · form4-08192026_120845.xml · derivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| August 14, 2026 Filed Aug 19, 2026 00:29 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000019 · form4-08192026_120845.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,269 | $29.45 | $37,377.00 |
DisclosureSEC source: 0001780088-26-000017 · form4-08052026_080835.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,422 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $29.54 per share, inclusive. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,907 | $28.95 | $171,008.24 |
DisclosureSEC source: 0001780088-26-000017 · form4-08052026_080835.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,691 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $29.35 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 500 | $33.27 | $16,633.90 |
DisclosureSEC source: 0001780088-26-000015 · form4-07062026_080747.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,598 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.37 per share, inclusive. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 6,728 | $32.62 | $219,433.72 |
DisclosureSEC source: 0001780088-26-000015 · form4-07062026_080747.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,098 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.18 to $33.05 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,795 | $30.58 | $54,891.10 |
DisclosureSEC source: 0001780088-26-000013 · form4-06032026_090641.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,826 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,243 | $32.79 | $73,547.97 |
DisclosureSEC source: 0001780088-26-000011 · form4-05052026_080522.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,621 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:12 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,838 | $32.66 | $60,029.08 |
DisclosureSEC source: 0001780088-26-000009 · form4-04032026_080432.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,864 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,365 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001780088-26-000006 · form4-03192026_100350.xml · derivative · entry 8 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,035 Underlying: Common Stock · 1,365 shares Expires 2028-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,461 | $29.99 | $43,815.39 |
DisclosureSEC source: 0001780088-26-000006 · form4-03192026_100350.xml · nonDerivative · entry 7 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,702 F6 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,365 | $2.19 | $2,989.35 |
DisclosureSEC source: 0001780088-26-000006 · form4-03192026_100350.xml · nonDerivative · entry 6 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 103 | $32.85 | $3,383.55 |
DisclosureSEC source: 0001780088-26-000006 · form4-03192026_100350.xml · nonDerivative · entry 5 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,798 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 483 | $31.79 | $15,353.99 |
DisclosureSEC source: 0001780088-26-000006 · form4-03192026_100350.xml · nonDerivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,901 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 6,100 | $31.28 | $190,831.18 |
DisclosureSEC source: 0001780088-26-000006 · form4-03192026_100350.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,384 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,587 | $33.38 | $86,342.16 |
DisclosureSEC source: 0001780088-26-000006 · form4-03192026_100350.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,484 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,577 | $32.74 | $117,108.83 |
DisclosureSEC source: 0001780088-26-000006 · form4-03192026_100350.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,071 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 10,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000004 · form4-03172026_090316.xml · derivative · entry 6 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,250 Underlying: Common Stock · 10,750 shares Expires 2029-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000004 · form4-03172026_090316.xml · derivative · entry 5 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000004 · form4-03172026_090316.xml · derivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000004 · form4-03172026_090316.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000004 · form4-03172026_090316.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 21:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000004 · form4-03172026_090316.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000002 · form4-02192026_090252.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001780088-26-000002 · form4-02192026_090252.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:51 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,989 | $31.35 | $62,345.80 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 5 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,798 F5 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:51 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,673 | $31.33 | $52,415.76 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,787 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:51 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 323 | $31.32 | $10,115.20 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,460 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:51 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,373 | $30.76 | $42,238.29 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,783 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,225 | $30.85 | $37,788.43 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 5 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,156 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 789 | $30.34 | $23,936.68 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,381 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:51 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionPerformance Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · derivative · entry 6 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F7 · derivative.exercise_date: Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:51 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 762 | $30.14 | $22,968.13 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,170 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,244 | $29.56 | $36,775.13 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,932 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 11,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · derivative · entry 6 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,981 shares Expires 2025-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F7 · derivative.exercise_date: 48,792 restricted stock units vested on December 1, 2024 and 11,981 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 01:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 11,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 100 | $29.35 | $2,935.00 |
DisclosureSEC source: 0001780088-25-000004 · form4-11052025_091154.xml · nonDerivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,195 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 600 | $27.54 | $16,524.00 |
DisclosureSEC source: 0001780088-25-000004 · form4-11052025_091154.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,295 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.60 per share, inclusive. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,455 | $26.02 | $37,859.97 |
DisclosureSEC source: 0001780088-25-000004 · form4-11052025_091154.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,895 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.79 to $26.50 per share, inclusive. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,776 | $25.22 | $95,246.58 |
DisclosureSEC source: 0001780088-25-000004 · form4-11052025_091154.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,350 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.74 to $25.65 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 4. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,343 | $23.64 | $126,316.00 |
DisclosureSEC source: 0001780088-25-000003 · form4-10032025_081034.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,126 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.40 to $24.08 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:53 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,501 | $19.87 | $109,325.22 |
DisclosureSEC source: 0001415889-25-023591 · form4-09032025_090900.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,469 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $20.34 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:13 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,805 | $18.24 | $51,157.59 |
DisclosureSEC source: 0001415889-25-022442 · form4-08202025_080828.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,970 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive. Read SEC document |
| August 14, 2025 Filed Aug 19, 2025 00:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionPerformance Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-022227 · form4-08192025_120854.xml · derivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.